By Judith E. Karp
This is a well timed compilation of latest innovations within the molecular pathogenesis and molecular treatment of acute myelogenous leukemia (AML). the point of interest is on chosen severe molecular determinants of AML pathogenesis and pathophysiology and the exploitation of those elements through varied healing brokers and modalities. there's an emphasis all through at the bidirectional circulate of information among the scientific and laboratory arenas.
Read Online or Download Acute Myelogenous Leukemia (Contemporary Hematology) PDF
Similar hematology books
VA clinical heart and the scientific collage of Georgia, Augusta. stories equipment most valuable for the analysis and administration of hematologic malignancies. tools are provided intimately for the professional researcher and the fewer skilled. DNLM: Lymphoma.
The potent prevention, prognosis, and administration of alloimmune cytopenias has develop into a staff attempt related to hematologists, obstetricians, pediatricians, immunologists, laboratory technicians, midwives, and learn scientists. This booklet has been written by way of specialists of their respective fields to collect the problems of pathogenesis, epidemiology, prevention, analysis, and scientific administration.
This creation to musculoskeletal imaging is an extra quantity within the studying Imaging sequence. Written in a trouble-free structure, it takes into consideration that musculoskeletal radiology is a subspecialty which has largely multiplied its scope and imaging services with the arrival of ultrasound, MRI, multidetector CT, and puppy.
It's been mostly approved that angiogenesis is considering the pathogenesis of hematological malignancies, like acute and persistent leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms and a number of myeloma. the level of angiogenesis within the bone marrow has been correlated with illness burden, diagnosis and therapy consequence.
- Experimental Hematology Today 1979
- Molecular Mechanisms of Angiogenesis: From Ontogenesis to Oncogenesis
- Clinical and Diagnostic Pathology of Graft-versus-Host Disease
- Microvascular Research Biology and Pathology, Two-Volume Set, Volume 1-2
- Diagnostic Lymph Node Pathology, Third Edition
Additional resources for Acute Myelogenous Leukemia (Contemporary Hematology)
Blood 2002;100:1233-1239. Pagel 1M, Appelbaum FR, Eary IF, et al. 131I-ANTI-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2005;107:2184-2191. Schwartz MA, Lovett DR, Redner A, et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. I Clin Onco11993; 11:294-303. Hall PD, Willingham MC, Kreitman Rl, Frankel AE.
Phosphorylation meets ubiquitination: the control of NF-(kappa) B activity. Annu Rev Immunol 2000;18:621-663. 152. Chang YC, Lee YS, Tejima T, et al. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 1998;9:79-84. 153. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Bioi Chern 2000;275:21,648-21,652. 154. Li B, Dou QP.
Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000; 19:6594--6599. 192. Powis G, Bonjouklian R, Berggren MM, et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3- kinase. Cancer Res 1994;54:2419-2423. 193. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4- morpholinyl)-8-phenyl-4H-l-benzopyran-4-one (LY294002). J Bioi Chern 1994;269:5241-5248. 194. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by Gl-arresting rapamycin-receptor complex.